By Steve Farrell2021-04-19T16:28:00+01:00
Who would have thought Aldi would sail dangerously close to the winds of intellectual property law with a product very reminiscent of someone else’s?
The whole world, it appears. Aldi has been having a field day making fun of M&S’s caterpillar cake High Court claim with its #FreeCuthbert Tweets. No-one seems in the least bit shocked at the alleged ‘trademark infringement’. Instead, they’re lapping up the suggestion that ‘Marks & Snitches’, as Aldi put it, has gone a bit OTT in its reaction.
After all, it’s not the first time Aldi has copied a popular product. Sometimes, it hasn’t paid off. In 2019, the discounter delisted its Moo Gourmet Yoghurt after Collective co-founder Amelia Harvey claimed the products looked too similar to the brand’s. That followed a similar row between sausage brand Heck and Aldi the previous year.
UK and US filings at the EPO fall over 2020
worldipreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from worldipreview.com Daily Mail and Mail on Sunday newspapers.
L UE veut construire son premier ordinateur quantique dans 5 ans Ce plan sera-t-il suffisant pour concurrencer les autres nations ?
developpez.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from developpez.com Daily Mail and Mail on Sunday newspapers.
The EU wants to build its first quantum computer That plan might not be ambitious enough
zdnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zdnet.com Daily Mail and Mail on Sunday newspapers.
Feb 02, 2021
Ben Edwards
In early-December, just weeks before AstraZeneca’s coronavirus vaccine began receiving regulatory approval around the world, the Cambridge-headquartered drugmaker agreed a $39-billion deal to buy US biotech firm Alexion.
The size of the transaction was driven, in part, by Alexion’s pipeline of rare blood disease treatments and its blockbuster drug Soliris. Such medicines are often the driver of bumper mergers and acquisitions in the pharmaceutical industry because of the power of patents, a type of intellectual property (IP) protection that prevents others from copying a product and selling their own version of it for a set number of years, typically two decades.